Introduction {#Sec1}
============

Rheumatoid arthritis (RA) is a chronic heterogeneous autoimmune disease characterized by progressive joint destruction. Serological tests, most notably the detection of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF), play an important role in diagnosing RA. ACPA were found in up to 75 % of RA patients \[[@CR1]\]. RF is present in 60--90 % of patients with established RA (esRA) and in up to 50 % of patients with early RA (eRA) \[[@CR2]\]. In contrast to ACPA the disease specificity of RF is relatively low, with 3--5 % of healthy adults showing the presence of RF in their serum, which increases to 10--30 % in the elderly \[[@CR3]\]. RF was also found in patients with other autoimmune and infectious diseases.

Earlier it was suggested that the sooner RA patients are treated the better their prognosis is \[[@CR4]\]. Although the introduction of ACPA and RF tests has greatly contributed to improving the early diagnosis of RA, additional molecular markers are needed, e.g., to identify seronegative patients, to differentiate between disease phenotypes, to predict responsiveness to treatment and to improve prognosis.

Circulating cell-free DNA (cfDNA), which is defined as extracellular DNA occurring in blood serum or plasma, has been widely studied and is considered as a potential biomarker for the detection and monitoring of various human diseases such as stroke \[[@CR7], [@CR8]\], myocardial infarction \[[@CR9]\], sepsis \[[@CR10]\] and acute pancreatitis \[[@CR11]\], as well as some chronic conditions such as cancer \[[@CR12]\]. Significantly higher cfDNA levels were found in the serum of cancer patients with advanced disease stages or metastases \[[@CR13]\] and it has been previously shown that circulating cfDNA carries tumor-specific genetic alterations \[[@CR14]\].

Circulating cfDNA molecules are present in only limited amounts in blood of healthy individuals, since dying cells and remnants of dead cells are efficiently removed, mainly in the liver \[[@CR5], [@CR6]\]. The origin and exact mechanism of cfDNA release are still controversial. Accumulation of cfDNA in plasma/serum might result from an excessive release of DNA caused by massive cell death, inefficient elimination of dead cells, extracellular DNA traps formed during inflammation, or a combination of these. Thus, the concentration of plasma/serum cfDNA might reflect the magnitude of cell damage and inflammation.

It is not known whether cfDNA can be used as a rapid and sensitive marker of RA. In analogy with cancer, elevated levels of circulating cfDNA have been hypothesized to occur in autoimmune diseases \[[@CR15]\]. Alteration of cfDNA levels has been reported for autoimmune diseases such as systemic lupus erythematosus (SLE), systemic sclerosis, Sjögren's syndrome \[[@CR16]\] and RA \[[@CR17]\]. The aim of the study described here was to quantify cfDNA levels in sera of eRA and esRA patients using both single-copy gene and Alu repetitive element analyses.

Method {#Sec2}
======

Patients {#Sec3}
--------

Sera from RA patients were obtained from four different centers. Samples from esRA patients were collected at the Radboud University Nijmegen Medical Center (*n* = 9), at the St. Maartenskliniek in Nijmegen (*n* = 10) and at the Catharina Hospital in Eindhoven (*n* = 8). Samples from 22 eRA patients were obtained from the Leiden Early Arthritis Clinic, an inception cohort of patients with recent onset arthritis (symptoms duration \<2 years) that was started at the Department of Rheumatology of the Leiden University Medical Center in 1993 and was described in detail previously \[[@CR18]\]. Samples from 20 eRA patients were collected at the Erasmus Medical Center in Rotterdam. As controls, a cohort of relapsing remitting multiple sclerosis patients (RRMS; collected at the Multiple Sclerosis Center Nijmegen; *n* = 44), and a group of healthy control individuals (collected at the Sanquin Blood Bank in Nijmegen; *n* = 50) were included. All RA patients fulfilled the American College of Rheumatology 1987 revised criteria for the classification of RA. Patient sera were used in accordance with the code of conduct of research with human material in The Netherlands. All subjects gave informed consent. Serum samples were aliquoted and stored at −80 °C prior to further use. Patient characteristics are summarized in Supplementary Table S1.

Serum cfDNA isolation and quantification {#Sec4}
----------------------------------------

Sera of 29 control subjects, 39 eRA, 26 esRA and 33 RRMS patients were used for cfDNA isolation. cfDNA was extracted from 200 μL of serum using the QIAamp DNA Blood Mini kit (Qiagen) according to the manufacturer's manual and was eluted with 50 µL of water. The amounts of isolated cfDNA were determined using real-time PCR analyses. Two different targets were chosen for quantification: a housekeeping gene, β-actin, and Alu repetitive elements. Three independent analyses were performed. Each PCR reaction was performed in a total volume of 10 µL containing 1 × GoTaq master mix (Promega), 0.75 µM of each primer, and 0.5--1 µL of cfDNA solution. The amplicons resulted in 115-bp (Alu) and 205-bp (β-actin) fragments \[see Table [1](#Tab1){ref-type="table"} for primer sequences; [@CR19]\]. Cycle threshold (Ct) values were measured with a StepOne Plus qPCR machine (software version 2.2; Applied Biosystems; Warrington, UK). Thermocycling was performed at 95 °C for 10 min (β-actin205) or for 2 min (Alu115), followed by 40 cycles at 95 °C for 15 s and 60 °C for 60 s. Each sample was analyzed in duplicate and negative controls were included in each run. Melting curve analysis was performed to confirm the specificity of PCR products. The absolute DNA concentration was calculated according to the standard curves obtained with parallel analyses of human genomic DNA (Qiagen) with concentrations varying from 0.005 to 10 ng/µL.Table 1Primers used for qPCR reactionForward primers (5′--3′)Reverse primers (5′--3′)Alu115CCTGAGGTCAGGAGTTCGAGCCCGAGTAGCTGGGATTACAβ-actin205GAGACCTTCAACACCCCAGCCGGATCTTCATGAGGTAGTCAG

The Ct values obtained for cfDNA samples were converted to serum cfDNA concentrations using the following formula \[[@CR20]\]:$$\documentclass[12pt]{minimal}
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DNase activity assay {#Sec5}
--------------------

Sera of 50 control subjects, 16 esRA and 44 RRMS patients were used for DNase activity assay. To determine serum total DNase activity, a single radial enzyme diffusion (SRED) method was used \[[@CR21]\]. This method is based on the principle that DNases present in serum samples are able to diffuse radially through a thin layer of agarose, which contains DNA, react with the DNA and hydrolyze it. Agarose gels (1.4 %; MetaPhor Agarose, Lonza) were prepared in buffer containing 20 mM Tris--HCl, pH 7.5, 2 mM MgCl~2~, 2 mM CaCl~2~, 100 ng/mL DNA from herring testes (Sigma-Aldrich) and GelStar stain (Cambrex). Wells (approx. 0.5 mm diameter) were punched in the gel. A standard curve was generated by serial dilutions of DNase I enzyme (Qiagen). Two microlitre of DNase I solution (concentration series) or serum samples were added to the wells. The gels were incubated in a humidified dark chamber at 37 °C for 24 h. GelStar fluorescence was visualized with a Doc-Print II System (Vilbert Lourmat). DNase activity was quantified by measuring the diameter of the non-stained circles resulting from DNA hydrolysis.

Statistical analysis {#Sec6}
--------------------

A statistical comparison of the data for the different groups was performed using GraphPad Prism software. For nonparametric comparisons, univariate analysis by the Mann--Whitney *U* test was performed. Differences were considered significant at *p* \< 0.05. The diagnostic sensitivity and specificity were determined by receiver operator characteristic (ROC) analysis.

Results {#Sec7}
=======

Serum cfDNA levels {#Sec8}
------------------

To determine the levels of cfDNA in sera, a quantitative real-time PCR approach was chosen for two different amplicons, one for Alu repeats and another for the β-actin gene. In addition to sera from esRA patients, sera from healthy individuals and from RRMS patients were used as controls; RRMS was chosen as another autoimmune disease with a different disease onset and with different treatment strategies. Alu repeats are highly repetitive sequences, which are found in approximately 10^6^ copies in the human genome, whereas β-actin is encoded by a single-copy gene. As shown in Figs. [1](#Fig1){ref-type="fig"}a and [2](#Fig2){ref-type="fig"}a, the cfDNA levels determined by the Alu amplicon (median 39 ng/mL; range 10--403 ng/mL) and by the β-actin amplicon (median 14 ng/mL; range 6--37 ng/mL) appeared to be much lower in the sera from esRA patients (*n* = 26) than in those from healthy controls (*n* = 26) and from RRMS patients (*n* = 33) (*p* \< 0.0001). RRMS sera showed similar levels of cfDNA as the healthy control sera (Figs. [1](#Fig1){ref-type="fig"}a, [2](#Fig2){ref-type="fig"}a; median 233 ng/mL (range 47--6900 ng/mL) and 206 ng/mL (range 42--899 ng/mL), respectively, for Alu115, and 188 ng/mL (range 18--3804 ng/mL) and 177 ng/mL (range 31--920 ng/mL), respectively, for β-actin205).Fig. 1Alu repeat-based detection of serum cfDNA. DNA was isolated from sera of healthy individuals (CTR), RA and RRMS patients and subjected to qPCR analysis with primers for the Alu115 amplicon (**a**). The *bars* indicate the median with interquartile range. \*\*indicates *p* \< 0.0001; ns indicates not significant. A ROC analysis was performed to discriminate RA patients from healthy controls (**b**)Fig. 2β-actin gene-based detection of serum cfDNA. DNA isolated from sera of healthy individuals (CTR), RA and RRMS patients was subjected to qPCR analysis with primers for the β-actin205 amplicon (**a**). The *bars* indicate the median with interquartile range. \*\*indicates *p* \< 0.0001; ns indicates not significant. A ROC analysis was performed to discriminate RA patients from healthy controls (**b**)

To assess whether the Alu115- and β-actin205-based qPCR assay for cfDNA can serve to discriminate RA patients from control individuals, receiver operating characteristic (ROC) analysis was applied (Figs. [1](#Fig1){ref-type="fig"}b, [2](#Fig2){ref-type="fig"}b, respectively). This analysis revealed that the area under the curve (AUC) values were high (AUC = 0.914 for Alu115 and AUC = 0.994 for β-actin205). It is important to note that the RA samples analyzed came from three distinct cohorts of esRA patients, which makes it unlikely that the differences observed are due to trivial factors associated with the handling and storage of the samples. The Alu115 and β-actin205 qPCR analyses do not seem to be useful to discriminate RRMS patients from healthy controls.

Previously, ACPA have been reported to discriminate between two distinct populations of RA patients \[[@CR22], [@CR23]\]. Therefore, we also compared cfDNA levels in patients with anti-cyclic citrullinated peptide (anti-CCP)-positive RA and anti-CCP-negative RA. No significant differences were observed between the levels of cfDNA in anti-CCP2-positive and anti-CCP2-negative RA sera (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3cfDNA concentration does not correlate with anti-CCP2 autoantibody status. Comparison of circulating Alu115 and β-actin205 DNA in sera from patients with anti-CCP2-positive (CCP+) and anti-CCP2-negative (CCP−) RA. The *bars* indicate the median with interquartile range. ns indicates not significant

The early diagnosis of RA and start of treatment is beneficial for patients to prevent or abrogate ongoing joint damage. Biomarkers which facilitate the early diagnosis of RA are needed in addition to ACPA. To study whether cfDNA levels were already decreased at the early stages of the disease, we determined cfDNA levels also in sera from eRA patients (*n* = 34) using the Alu115 and β-actin205 primer sets and performed additional analyses with material from healthy controls (*n* = 29). The results demonstrated that there was no significant difference between serum cfDNA levels of healthy individuals and eRA patients (Fig. [4](#Fig4){ref-type="fig"}). Comparison of eRA (*n* = 39) and esRA (*n* = 24) samples, however, showed much lower serum cfDNA levels for esRA patients than the levels in the eRA samples (Fig. [5](#Fig5){ref-type="fig"}). Thus, the reduction of cfDNA levels appears to occur after disease onset.Fig. 4cfDNA in early RA. DNA isolated from sera of healthy subjects (CTR) and eRA patients was analysed by qPCR using Alu115 primers (**a**) or β-actin205 primers (**b**). ns indicates not significantFig. 5Comparison of cfDNA concentration in sera of eRA and esRA patients. Serum cfDNA was purified and analysed by qPCR using Alu115 primers (**a**) or β-actin205 primers (**b**)

Serum DNase activity {#Sec9}
--------------------

The reduced serum cfDNA levels in esRA might be explained by elevated levels and/or activity of nucleases present in the sera. Deoxyribonuclease I (DNase I) is one of the predominant DNases in human serum \[[@CR24]\]. Deficiency in DNase I enzyme, and the resulting enhanced levels of cfDNA associated with nuclear antigens, promotes susceptibility to autoimmune disorders \[[@CR25]\]. To investigate whether the reduced serum cfDNA levels were due to enhanced DNase activity in the sera, a radial enzyme diffusion method was carried out with sera from healthy controls (*n* = 50) and from esRA (*n* = 16) and RRMS (*n* = 44) patients. The sera were loaded on a gel containing DNA, and, after incubation at 37 °C, DNA hydrolysis by nucleases present in the sera was visualized using a fluorescent dye. The results showed that no significant differences in total DNase activity between these groups were observed (Fig. [6](#Fig6){ref-type="fig"}). Thus, the reduced levels of cfDNA in esRA sera do not seem to be due to elevated DNase activities.Fig. 6DNase activity in sera from healthy individuals (CTR), RA and RRMS patients. The SRED method was used to determine the DNase activity in the sera. Sera were applied to wells in a 1.4 % agarose gel containing DNA and a DNA-staining dye and incubated in a humidified chamber at 37 °C for 24 h. Subsequently, the radius of the non-fluorescent area surrounding each well was measured

Discussion {#Sec10}
==========

In the present study, we found reduced levels of serum cfDNA in established RA compared to healthy controls, early RA patients and RRMS patients. Lower levels of cfDNA have been reported before to occur in sera from SLE as well as in sera from RA patients in comparison with healthy subjects \[[@CR26]\]. In addition, when nucleosome plasma levels were assessed by ELISA, nucleosomes appeared to be hardly detectable in the plasma of patients with RA in comparison with SLE patients \[[@CR27]\]. Paradoxically, other studies showed a substantial increase in cfDNA concentration in plasma or serum of RA patients \[[@CR16], [@CR17], [@CR28]\]. Leon et al. \[[@CR28]\] reported that relatively high levels of cfDNA were found in patients with more severe symptoms who had active RA for less than 10 years, whereas patients with longer duration of disease showed a lower level of cfDNA. Elevated DNA levels were found more frequently in patients seronegative for rheumatoid factor (RF). Zhong et al. \[[@CR17]\] found higher concentrations of cfDNA in serum and plasma of RA patients in comparison with healthy controls. These conflicting data on serum cfDNA levels in RA may at least in part be explained by the use of different techniques (for example, qPCR, ELISA or UV-spectrophotometry) and the different DNA targets chosen to perform the analyses. The PCR assay measures only amplifiable DNA, i.e., DNA fragments with a sufficient size and devoid of simple sequence repeats, whereas the assays based on spectrophotometry detect the total nucleic acid content such as dsDNA, ssDNA, and RNA. In addition, differences in the state of disease progression and/or activity at the time of sampling may have affected the results, as indicated by the differences observed for eRA and esRA. Moreover, differences in sample processing and storage might have introduced preanalytical biases. However, Sjoholm et al. \[[@CR29]\] demonstrated that plasma and serum samples that were stored for 10--30 years produced reliable results when the cfDNA was extracted and amplified with PCR. In this respect we should also stress that samples collected in different centers were used in our study, which reduces the chance for such biases. Nevertheless, replication studies with distinct clinical cohorts are needed to support our findings. In addition, the analysis of larger groups may increase the statistical significance of our data.

We also observed slight overrepresentation of DNA quantified by the Alu repeats in sera in comparison with DNA quantified by the β-actin qPCR (see Fig. [3](#Fig3){ref-type="fig"}). However, the Alu115 and β-actin205 concentrations were highly correlated with each other for all groups tested (Supplementary Fig. S1). Our results are in agreement with previously reported observations. The proportion of Alu repeats relative to the β-globin gene was larger in serum DNA than in lymphocyte DNA, both in control subjects and in cancer patients \[[@CR30]\]. In addition, overrepresentation of Alu repeats in serum cfDNA, in comparison with the complete human genome, was shown before for 50 healthy individuals \[[@CR31]\]. The consistently higher levels of qPCR-quantified DNA resulting from the Alu repeat analysis compared to the β-actin gene might be due to the fragmentation of DNA in serum. The chance that a complete Alu115 amplicon is present in a single DNA fragment is not only higher as a result of its size (115 basepairs compared to 205 basepairs for β-actin), but also due to the presence of multiple copies of the Alu115 amplicon in the human genome.

The exact mechanism by which DNA is released in blood is unknown. Previously, it has been demonstrated that the DNA in serum/plasma is predominantly hematopoietic in origin \[[@CR32]\]. Four processes that may lead to the generation of circulating DNA have been suggested: cell death (necrosis or apoptosis) or tissue injury, active secretion of DNA by leukocytes, enucleation (a process in which the nuclei are expelled by erythroblasts during the course of maturation) and NETosis (a process in which neutrophils discharge extracellular traps).

Because we observed reduced levels of cfDNA in esRA patients, but not in eRA patients, it is tempting to speculate about a role for drug treatment. Methotrexate (MTX) is the most common disease-modifying anti-rheumatic drug (DMARD) used to treat RA. It reduces inflammation and inhibits enzymes involved in nucleoside/nucleotide metabolism. Previously, it has been shown that patients with RA, treated with MTX, display low concentrations of circulating purines and pyrimidines, with consequent reduced availability for DNA and RNA synthesis and cell proliferation \[[@CR33]\]. Therefore, it will be very interesting to investigate whether the decrease of cfDNA in sera of esRA patients correlates with MTX treatment and dosage. In this respect, it is also important to note that the RRMS patients, which are only infrequently treated with MTX (only as a second line treatment), do not show altered cfDNA levels. None of the RRMS patients analyzed received MTX. The following processes might also cause the reduced levels of cfDNA in esRA patients: (1) increase of cfDNA degradation/elimination due to increased levels of circulating nuclease activity. However, we did not observe differences in the activity of serum nucleases between eRA and esRA patients and control individuals. (2) Increase of cfDNA degradation/elimination due to increased levels of serum anti-dsDNA antibodies. These antibodies can influence the level of circulating nucleosomes. An inverse correlation between anti-dsDNA antibody levels and concentrations of circulating DNA in SLE patients was observed \[[@CR26]\]. RA patients can also develop anti-dsDNA antibodies induced by anti-TNFα biological therapies. They are usually of low avidity and are detectable transiently after treatment \[[@CR34]\]. (3) Increase of cfDNA degradation/elimination due to enhanced metabolic activity and the generation of reactive oxygen species (ROS) by blood cells. It has been shown that DNA degradation products are elevated in leukocytes and sera of RA patients \[[@CR35]\]. Moreover, increased oxidative enzyme activity along with decreased antioxidant levels in sera and synovial fluid of RA patients was observed. Higher levels of ROS in sera of esRA patients can change cfDNA degradation and lead to decreased cfDNA concentrations in sera. (4) Decreased apoptosis/necrosis of blood cells. Altered apoptosis susceptibility of peripheral blood mononuclear cells for various systemic autoimmune diseases has been previously shown. The presence of activated peripheral blood T lymphocytes with impaired apoptosis, resulting in long-lived T cells peripherally in RA was reported \[[@CR36]\]. Reduced apoptosis has been also detected in synovial tissues from patients with RA \[[@CR37]\]. (5) Different susceptibility to degradation of various forms of circulating DNA such as shed cells, apoptotic bodies, nucleosomes, other nucleoproteins, and free DNA which exists in serum/plasma. The various forms of cfDNA might differ between healthy control and RA patients and the fates of different cfDNA forms are unknown.

In conclusion, the quantitative changes in serum cfDNA may be helpful as disease progression markers. Potential correlations between cfDNA levels and clinical features, such as disease activity, erosiveness and response to treatment, still need to be explored. It will be interesting to investigate whether the changes in cfDNA levels are affected by drugs used to treat RA patients. To further explore these possibilities, longitudinal studies will be necessary to get more insight in the time course of the reduction of cfDNA levels and the effects of drugs on these changes.
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